ADD THIS DRUG TO MY LIST

Select the drug indication to add to your list

BYDUREON
Diabetes
Compare To Related Drugs
View/Edit/Compare Drugs In My List

Only 4 drugs may be compared at once

Drug Name:

BYDUREON Rx

Generic Name and Formulations:
Exenatide ext-rel 2mg; per vial or pen; for injectable suspension.

Company:
AstraZeneca Pharmaceuticals

Therapeutic Use:

Indications for BYDUREON:

Adjunct to diet and exercise, to improve glycemic control in adults with type 2 diabetes.

Limitations Of use:

Not recommended as first-line therapy for patients inadequately controlled on diet and exercise. Not a substitute for insulin. Not for treating type 1 diabetes or diabetic ketoacidosis. Not studied in combination with prandial insulin or with history of pancreatitis.

Adult:

Give by SC inj in abdomen, thigh, or upper arm; rotate inj sites. Inject immediately after mixing. 2mg once every 7 days (weekly). Changing from Byetta: discontinue, then start Bydureon.

Children:

Not recommended.

Contraindications:

History (personal or family) of medullary thyroid carcinoma. Multiple endocrine neoplasia syndrome type 2.

Boxed Warning:

Risk of thyroid C-cell tumors.

Warnings/Precautions:

Risk of thyroid C-cell tumors possible; monitor. History of pancreatitis; consider other antidiabetics. Monitor for pancreatitis; discontinue if suspected; do not restart if confirmed. History of anaphylaxis or angioedema with another GLP-1 agonist; monitor closely. Severe GI disorders, renal impairment (CrCl <30mL/min), end-stage renal disease: not recommended. Renal transplantation. Moderate renal impairment. Elderly. Pregnancy. Nursing mothers.

See Also:

BYDUREON BCISE

Pharmacological Class:

Glucagon-like peptide-1 (GLP-1) receptor agonist.

Interactions:

Do not mix with insulins; avoid adjacent inj sites. Increased risk of hypoglycemia with concomitant insulin secretagogues (eg, sulfonylureas) or insulin; may need lower dose of these. May delay absorption of oral drugs (eg, acetaminophen). Monitor INR more frequently with warfarin.

Adverse Reactions:

Nausea, diarrhea, headache, vomiting, constipation, dyspepsia, inj site reactions (eg, pruritus, nodule); acute kidney injury, renal impairment, pancreatitis (may be fatal), hypersensitivity reactions (discontinue if occur), possible antibody formation (glycemic response may be attenuated).

Generic Availability:

NO

How Supplied:

Single-dose trays—4 (each contains 1 vial, 1 prefilled syringe with diluent + supplies); Single-dose pens—4 (each contains 1 Bydureon Pen + 1 needle); BCise single-dose autoinjectors—4


Data provided by MPR.

Sign Up for Free e-newsletters



Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs